The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Proteomic analyses of cardiac ATTR and AL amyloidosis: key findings and clinical implications
Taxiarchis Kourelis, MD, Mayo Clinic, Rochester, MN, discusses proteomic analyses of cardiac transthyretin (ATTR) and light chain (AL) amyloidosis. Using data-independent acquisition proteomics on cardiac biopsies from AL and ATTR cohorts, the study identified significant differences between advanced disease cases and those with better outcomes. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding Pfizer
